VivoSim Labs (VIVS) Change in Accured Expenses (2010 - 2026)
VivoSim Labs (VIVS) posted quarterly Change in Accured Expenses of $163000.0 for Q1 2026, down 22.75% year-over-year from $211000.0 in Q1 2025, and up 246.81% quarter-over-quarter from $47000.0 in Q4 2025.
VivoSim Labs (VIVS) Change in Accured Expenses (2010 - 2026) Analysis & Trends
VivoSim Labs' Change in Accured Expenses history runs 17 years deep, the most recent figure standing at $163000.0 for Q1 2026.
- In Q1 2026, Change in Accured Expenses fell 22.75% year-over-year to $163000.0; the TTM figure through Mar 2026 stood at -$245000.0 (down 134.17% YoY), while the FY2026 annual figure was -$245000.0, down 134.17% from the prior year.
- Change in Accured Expenses for Q1 2026 stood at $163000.0, up from $47000.0 in the prior quarter.
- The five-year high for Change in Accured Expenses was $2.2 million in Q1 2023, with the low at -$2.1 million in Q2 2023.
- The 5-year median for Change in Accured Expenses is $54000.0 (2023), against an average of $17062.5.
- The sharpest annual moves came in 2022 and 2023: Change in Accured Expenses tumbled 2086.36% in 2022, then surged 603.89% in 2023.
- VivoSim Labs' Change in Accured Expenses stood at $184000.0 in 2022, then tumbled by 66.85% to $61000.0 in 2023, then soared by 480.33% to $354000.0 in 2024, then tumbled by 86.72% to $47000.0 in 2025, then jumped by 246.81% to $163000.0 in 2026.
- Business Quant data shows VIVS's Change in Accured Expenses at $163000.0 in Q1 2026, $47000.0 in Q4 2025, and $44000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | VivoSim Labs | 1.49 Mn | 1.49 Mn | - | -243,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -243,000.00 |
| Jun 30, 2026 | -243,000.00 |
| Mar 31, 2026 | 163,000.00 |
| Mar 31, 2026 | 163,000.00 |
| Dec 31, 2025 | 47,000.00 |
| Dec 31, 2025 | 47,000.00 |
| Sep 30, 2025 | 44,000.00 |
| Sep 30, 2025 | 44,000.00 |
| Jun 30, 2025 | -499,000.00 |
| Jun 30, 2025 | -499,000.00 |
| Mar 31, 2025 | 211,000.00 |
| Mar 31, 2025 | 211,000.00 |
| Dec 31, 2024 | 354,000.00 |
| Dec 31, 2024 | 354,000.00 |
| Sep 30, 2024 | 475,000.00 |
| Sep 30, 2024 | 475,000.00 |
| Jun 30, 2024 | -323,000.00 |
| Jun 30, 2024 | -323,000.00 |
| Dec 31, 2023 | 61,000.00 |
| Dec 31, 2023 | 61,000.00 |